Filing Flows › Angiodynamics (ANGO) › Q1 FY27
Angiodynamics (ANGO) Q1 FY27 earnings results (first quarter fiscal 2027)
10-Q filed Oct 8, 2026
Angiodynamics (ANGO) reported revenue of $80.9M for the first quarter fiscal 2027 (Q1 FY27), +7% from a year earlier and -7% from the quarter before. Operating margin was -9.0%, net loss $7.1M (8.8% of revenue).
Angiodynamics, Q1 FY27: revenue $80.9M (+7% year over year), operating margin -9.0%, net loss $7.1M, operating cash flow −$15.3M. The chart follows the revenue to costs, profit and cash.
| Q1 FY27 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $80.9M | -7% | +7% |
| Operating profit | −$7.3M | — | — |
| Net earnings | −$7.1M | — | — |
| Operating cash flow | −$15.3M | -188% | — |
What changed
Revenue was $80.9M in Q1 FY27, up 7% year over year and down 7% from the previous quarter. Med Device was the largest line at 51% of revenue. Med Tech added $4.7M year over year (up 13%), 89% of the total change.
Gross margin was 59.4%, up 4.1 points from Q1 FY26. Operating costs exceeded revenue by $7.3M, an operating margin of -9.0%. Operating expenses grew 5% against revenue growth of 7%. The fastest-growing cost line was Research & development (+24%). The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $11.4M loss.
Operating cash flow was −$15.3M. Non-cash charges added back $5.5M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items used $18.2M. Capital expenditures of $379K exceeded it, leaving free cash flow of −$15.7M.
Questions
What was Angiodynamics' revenue in the first quarter fiscal 2027?
Angiodynamics (ANGO) reported revenue of $80.9M for the first quarter fiscal 2027 (Q1 FY27), +7% from a year earlier and -7% from the quarter before.
Was Angiodynamics profitable in the first quarter fiscal 2027?
Operating loss was $7.3M (-9.0% of revenue) and net loss $7.1M.
Source: Angiodynamics 10-Q on SEC EDGAR.